Effect of serum interleukin-1 receptor antagonist level on survival of patients with non-small cell lung cancer

Yigit,Murat; Değirmencioğlu,Serkan; Ugurlu,Erhan; Yaren,Arzu

doi:10.3892/mco.2017.1195

Effect of serum interleukin-1 receptor antagonist level on survival of patients with non-small cell lung cancer

Authors:
- Murat Yigit
- Serkan Değirmencioğlu
- Erhan Ugurlu
- Arzu Yaren
View Affiliations

Affiliations: Department of Internal Medicine, Pamukkale University, Affiliated to Pamukkale University Hospital, Bagbasi, Denizli 20070, Turkey, Fahri Goksin Oncology Center, Pamukkale University, Affiliated to Pamukkale University Hospital, Bagbasi, Denizli 20070, Turkey, Department of Thoracic Oncology, Pamukkale University, Affiliated to Pamukkale University Hospital, Bagbasi, Denizli 20070, Turkey
Published online on: March 15, 2017 https://doi.org/10.3892/mco.2017.1195
Pages: 708-712

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Due to poor prognosis in advanced non-small cell lung cancer (NSCLC), new effective markers are required in the monitoring of the disease. The present study aimed to investigate the association between the serum IL-1 receptor antagonist (IL-1Ra) level, overall survival (OS), and treatment response in NSCLC, and to evaluate the usefulness of the serum IL-1Ra level as a prognostic marker for NSCLC. Eighty patients (72 men and 8 women) and 40 healthy volunteers (13 men and 27 women) were included in the present study. The median progression-free survival was 16 weeks for patients with high serum IL-1Ra levels, and 35 weeks for patients with low serum IL-1Ra levels (P=0.027). The median OS was 38 weeks in patients with a high serum IL-1Ra level, and 62 weeks in patients with a low serum IL-1Ra level (P=0.065). The results of the present study have demonstrated that there was a significant correlation between IL-1Ra levels and NSCLC progression and survival, although the correlation between IL-1Ra levels and the response to treatment was not statistically significant. Therefore, the pre-treatment IL-1Ra level has been identified as a putative prognostic factor for NSCLC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
2	Shiels MS, Pfeiffer RM, Hildesheim A, Engels EA, Kemp TJ, Park JH, Katki HA, Koshiol J, Shelton G, Caporaso NE, et al: Circulating inflammation markers and prospective risk for lung cancer. J Natl Cancer Inst. 105:1871–1880. 2013. View Article : Google Scholar : PubMed/NCBI
3	Straif K, Benbrahim-Tallaa L, Baan R, Grosse Y, Secretan B, El Ghissassi F, Bouvard V, Guha N, Freeman C, Galichet L, et al: WHO International Agency for Research on Cancer Monograph Working Group: A review of human carcinogens--Part C: Metals, arsenic, dusts, and fibres. Lancet Oncol. 10:453–454. 2009. View Article : Google Scholar : PubMed/NCBI
4	Edge SB, Byrd DR, Compton CC, et al: AJCC Cancer Staging Manual. 7th. Springer; New York: 2010
5	Yotsukura M, Ohtsuka T, Kaseda K, Kamiyama I, Hayashi Y and Asamura H: Value of the Glasgow Prognostic Score as a Prognostic Factor in Resectable Non-Small Cell Lung Cancer. J Thorac Oncol. 11:1311–1318. 2016. View Article : Google Scholar : PubMed/NCBI
6	Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, Chen H, Fujimoto J, Kugler K, Franklin WA, et al: LCMC Investigators: Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol. 10:768–777. 2015. View Article : Google Scholar : PubMed/NCBI
7	Dinarello CA: Biologic basis for interleukin-1 in disease. Blood. 87:2095–2147. 1996.PubMed/NCBI
8	Konishi N, Miki C, Yoshida T, Tanaka K, Toiyama Y and Kusunoki M: Interleukin-1 receptor antagonist inhibits the expression of vascular endothelial growth factor in colorectal carcinoma. Oncology. 68:138–145. 2005. View Article : Google Scholar : PubMed/NCBI
9	Barillé S, Akhoundi C, Collette M, Mellerin MP, Rapp MJ, Harousseau JL, Bataille R and Amiot M: Metalloproteinases in multiple myeloma: Production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. Blood. 90:1649–1655. 1997.PubMed/NCBI
10	Apte RN and Voronov E: Interleukin-1--a major pleiotropic cytokine in tumor-host interactions. Semin Cancer Biol. 12:277–290. 2002. View Article : Google Scholar : PubMed/NCBI
11	Dinarello CA: Interleukin-1 and interleukin-1 antagonism. Blood. 77:1627–1652. 1991.PubMed/NCBI
12	Lewis AM, Varghese S, Xu H and Alexander HR: Interleukin-1 and cancer progression: The emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J Transl Med. 4:482006. View Article : Google Scholar : PubMed/NCBI
13	Voronov E, Carmi Y and Apte RN: Role of IL-1-mediated inflammation in tumor angiogenesis. Adv Exp Med Biol. 601:265–270. 2007. View Article : Google Scholar : PubMed/NCBI
14	Smith DR, Kunkel SL, Standiford TJ, Chensue SW, Rolfe MW, Orringer MB, Whyte RI, Burdick MD, Danforth JM, Gilbert AR, et al: The production of interleukin-1 receptor antagonist by human bronchogenic carcinoma. Am J Pathol. 143:794–803. 1993.PubMed/NCBI
15	Fuksiewicz M, Kaminska J, Kotowicz B, Kowalska M, Rubach M and Pienkowski T: Serum cytokine levels and the expression of estrogen and progesterone receptors in breast cancer patients. Clin Chem Lab Med. 44:1092–1097. 2006. View Article : Google Scholar : PubMed/NCBI
16	Barber MD, Ross JA and Fearon KC: Changes in nutritional, functional, and inflammatory markers in advanced pancreatic cancer. Nutr Cancer. 35:106–110. 1999. View Article : Google Scholar : PubMed/NCBI
17	Bruserud O, Aasen I, Akselsen PE, Bergheim J, Rasmussen G and Nesthus I: Interleukin 1 receptor antagonist (IL1RA) in acute leukaemia: IL1RA is both secreted spontaneously by myelogenous leukaemia blasts and is a part of the acute phase reaction in patients with chemotherapy-induced leucopenia. Eur J Haematol. 57:87–95. 1996. View Article : Google Scholar : PubMed/NCBI
18	Danis VA, Millington M, Hyland VJ and Grennan D: Cytokine production by normal human monocytes: Inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol. 99:303–310. 1995. View Article : Google Scholar : PubMed/NCBI
19	Hu Z, Shao M, Chen Y, Zhou J, Qian J, Xu L, Ma H, Wang X, Xu Y, Lu D, et al: Allele 2 of the interleukin-1 receptor antagonist gene (IL1RN*2) is associated with a decreased risk of primary lung cancer. Cancer Lett. 236:269–275. 2006. View Article : Google Scholar : PubMed/NCBI
20	Hurme M and Santtila S: IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1β genes. Eur J Immunol. 28:2598–2602. 1998. View Article : Google Scholar : PubMed/NCBI
21	Lind H, Zienolddiny S, Ryberg D, Skaug V, Phillips DH and Haugen A: Interleukin 1 receptor antagonist gene polymorphism and risk of lung cancer: A possible interaction with polymorphisms in the interleukin 1 beta gene. Lung Cancer. 50:285–290. 2005. View Article : Google Scholar : PubMed/NCBI
22	McKeown DJ, Brown DJ, Kelly A, Wallace AM and McMillan DC: The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer. Br J Cancer. 91:1993–1995. 2004. View Article : Google Scholar : PubMed/NCBI
23	Herfs M, Hubert P, Poirrier AL, Vandevenne P, Renoux V, Habraken Y, Cataldo D, Boniver J and Delvenne P: Proinflammatory cytokines induce bronchial hyperplasia and squamous metaplasia in smokers: Implications for chronic obstructive pulmonary disease therapy. Am J Respir Cell Mol Biol. 47:67–79. 2012. View Article : Google Scholar : PubMed/NCBI